MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

2019 ◽  
Author(s):  
Keyword(s):  
Kidney Transplant ◽  
Human Cytomegalovirus ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection

scholarly journals CD4+T cell levels are decreased during active CMV infection in kidney transplant recipients

2002 ◽  
Vol 34 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Sahar Essa ◽  
Alexander S Pacsa ◽  
Raj Raghupathy ◽  
Raja'a Al-Attiyah ◽  
Amany El-Shazly ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Cd4 T Cell ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection

Early and Rapid Diagnosis of CMV Infection by Nonradioactive in situ Hybridization in Pediatric Kidney Transplant Recipients

Nephron ◽  
1992 ◽  
Vol 60 (1) ◽  
pp. 25-29
Author(s):  
L. Murer ◽  
G. Zacchello ◽  
G. Basso ◽  
G. Palù ◽  
A. Barbato ◽  
...  
Keyword(s):  
In Situ Hybridization ◽  
Kidney Transplant ◽  
Rapid Diagnosis ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection ◽  
Nonradioactive In Situ Hybridization

scholarly journals Impacts of Interleukin-18 Polymorphisms on the Incidence of Delayed-Onset Cytomegalovirus Infection in a Cohort of Kidney Transplant Recipients

2019 ◽  
Vol 6 (9) ◽  
Author(s):  
Isabel Pérez-Flores ◽  
Jose Luis Santiago ◽  
Cristina Fernández-Pérez ◽  
Elena Urcelay ◽  
María Ángeles Moreno de la Higuera ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Cytomegalovirus Infection ◽  
Disease Incidence ◽  
Defense Responses ◽  
Solid Organ ◽  
Nucleotide Polymorphisms ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection ◽  
Delayed Onset

Abstract Background The incidence of cytomegalovirus (CMV) infection in solid organ transplant recipients may be reduced by antiviral prophylaxis, but this strategy may lead to delayed-onset CMV infection. The proinflammatory cytokine interleukin (IL)-18 plays a major role in viral host defense responses. This study examines the impacts of 2 single-nucleotide polymorphisms (SNPs) in the promoter region of the IL-18 gene, -607C/A (rs1946518) and -137G/C (rs187238), on the incidence of delayed-onset CMV infection in patients undergoing kidney transplant. Methods This retrospective study analyzed 2 IL-18 SNPs in consecutive adult kidney transplant recipients using real-time polymerase chain reaction with TaqMan probes. Participants were enrolled over the period 2005–2013 and stratified according to their IL-18 SNP genotype. The concordance index (Harrell’s c-index) was used as a measure of the discriminatory power of the predictive models constructed with bootstrapping to correct for optimistic bias. Results Seven hundred nine patients received transplants in the study period, and 498 met selection criteria. Cytomegalovirus infection and disease incidence were 38% and 7.5%, respectively. In multivariate competing risk regression models, carriers of the -607C/-137G haplotype who received prophylaxis showed a higher incidence of CMV replication after antiviral agent discontinuation (hazard ratio = 2.42 [95% confidence interval, 1.11–5.26]; P = .026), whereas CMV disease was not observed in those given prophylaxis who were noncarriers of this polymorphism (P = .009). Conclusions Our findings suggest that the -607C/-137G IL-18 haplotype is associated with a higher incidence of postprophylaxis CMV replication. The prior identification of this polymorphism could help select alternative measures to prevent delayed-onset CMV infection in these patients.

The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis

2020 ◽  
Vol 104 (10) ◽  
pp. 2139-2147 ◽  
Author(s):  
Mayara I. de Paula ◽  
Sunjae Bae ◽  
Ashton A. Shaffer ◽  
Jacqueline Garonzik-Wang ◽  
Claudia R. Felipe ◽  
...  
Keyword(s):  
High Risk ◽  
Kidney Transplant ◽  
Antithymocyte Globulin ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection ◽  
Pharmacological Prophylaxis

Clinical correlations of human cytomegalovirus strains and viral load in kidney transplant recipients

2009 ◽  
Vol 9 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Eliana Nogueira ◽  
Kikumi Suzete Ozaki ◽  
Helena Tomiyama ◽  
Niels Olsen Saraiva Câmara ◽  
Celso Francisco Hernandes Granato
Keyword(s):  
Viral Load ◽  
Kidney Transplant ◽  
Human Cytomegalovirus ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Clinical Correlations

scholarly journals Common Features of γδ T Cells and CD8+αβ T Cells Responding to Human Cytomegalovirus Infection in Kidney Transplant Recipients

2009 ◽  
Vol 200 (9) ◽  
pp. 1415-1424 ◽  
Author(s):  
Lionel Couzi ◽  
Vincent Pitard ◽  
Sonia Netzer ◽  
Isabelle Garrigue ◽  
Marie‐Edith Lafon ◽  
...  
Keyword(s):  
T Cells ◽  
Kidney Transplant ◽  
Human Cytomegalovirus ◽  
Cytomegalovirus Infection ◽  
Γδ T Cells ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Common Features ◽  
Human Cytomegalovirus Infection ◽  
Αβ T Cells

scholarly journals MONITORING OF CMV INFECTION IN KIDNEY TRANSPLANT RECIPIENTS

2017 ◽  
Vol 23 (4) ◽  
pp. 1834-1838
Author(s):  
Zhivka Stoykova ◽  
◽  
Liliya Ivanova ◽  
Valentin Ikonomov ◽  
Iliana Teodorova ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection

scholarly journals Every-Other-Day Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Kidney Transplant Recipients: A Single-Center Experience

2021 ◽  
Vol 8 (3) ◽  
Author(s):  
Bhuwania P ◽  
Keyword(s):  
Kidney Transplant ◽  
Opportunistic Infections ◽  
High Dose ◽  
Transplant Recipients ◽  
Single Center ◽  
Kidney Transplant Recipients ◽  
Cmv Infection ◽  
Moderate Risk ◽  
Single Center Experience ◽  
Positive Antibody

Background: Moderate-risk for Cytomegalovirus (CMV) infection includes patients with donor positive/recipient positive (D+/R+) or donor negative/ recipient positive antibody status (D-/R+). Guidelines recommend high-dose daily Valganciclovir (VGCV) as prophylaxis, which may be due to the paucity of data on the efficacy of every-other-day VGCV. Methods: Our experience of using every-other-day VGCV as a prophylactic strategy in moderate risk Kidney Transplant Recipients (KTR) has been described. We retrospectively reviewed 86 moderate-risk KTR in our institution between 2018 and 2020. CMV infection at 6 months post-transplant was the primary endpoint. Graft survival, biopsy-proven rejection, opportunistic infections, Haematological adverse events, and mortality were also evaluated. Results: CMV infection occurrence at 6 months was zero in our cohort. Incidence of leukopenia was 13%, BPAR-31%, OI-33%, and mortality being 3.5%. Conclusion: Every-Other-Day VGCV dosing can be an effective alternative in moderate risk KTR for CMV prevention.

Sign in / Sign up

Export Citation Format

Share Document